Media coverage about American Renal Associates Holdings (NYSE:ARA) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. American Renal Associates Holdings earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.3386486318074 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.

Shares of American Renal Associates Holdings (NYSE:ARA) traded down 0.66% during trading on Monday, reaching $15.00. 226,590 shares of the company’s stock traded hands. American Renal Associates Holdings has a 1-year low of $14.77 and a 1-year high of $25.42. The company’s market capitalization is $467.27 million. The company has a 50 day moving average of $18.11 and a 200-day moving average of $18.36.

American Renal Associates Holdings (NYSE:ARA) last posted its earnings results on Tuesday, May 9th. The company reported $0.06 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by $0.04. The company had revenue of $177 million during the quarter, compared to the consensus estimate of $184.67 million. American Renal Associates Holdings had a negative net margin of 2.13% and a positive return on equity of 20.97%. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.16 earnings per share. Equities analysts predict that American Renal Associates Holdings will post $0.53 earnings per share for the current year.

Several equities analysts have issued reports on the stock. Zacks Investment Research raised shares of American Renal Associates Holdings from a “sell” rating to a “hold” rating in a research note on Wednesday, May 10th. Wells Fargo & Company raised shares of American Renal Associates Holdings from a “market perform” rating to an “outperform” rating in a research note on Thursday, May 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $25.50.

WARNING: “American Renal Associates Holdings (ARA) Getting Somewhat Positive Media Coverage, Analysis Shows” was published by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at

American Renal Associates Holdings Company Profile

American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.

Receive News & Ratings for American Renal Associates Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates Holdings Inc and related companies with's FREE daily email newsletter.